Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
Extended lab space for product development, customer demos, and training
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
Subscribe To Our Newsletter & Stay Updated
